LISA WYDRA: Open Payments
NPI 1780916916 · HAZLET, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$761 in 44 payments from 16 companies in 2025. Trend: 2023 $71 · 2024 $779 · 2025 $761
Food & beverage: $741Consulting: $20
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $198 |
| Novartis Pharmaceuticals Corporation | 4 | $76 |
| CSL Behring | 3 | $58 |
| Amgen Inc. | 3 | $52 |
| Genentech USA, Inc. | 3 | $51 |
| AstraZeneca Pharmaceuticals LP | 3 | $50 |
| GENZYME CORPORATION | 2 | $48 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
Products named: TRELEGY ELLIPTA, DUPIXENT, TEZSPIRE, Xolair, FASENRA, NEFFY, NUCALA, Hizentra.
Industry payments across NJ — which companies pay providers there.
